SlideShare a Scribd company logo
1 of 20
Download to read offline
Anteo Diagnostics Limited (ASX:ADO)
March 2015
Presented by
Dr Geoff Cumming
CEO
Forward Looking Statement
The purpose of the presentation is to provide an update of the business of Anteo Diagnostics (ASX:ADO).
These slides have been prepared as a presentation aid only and the information they contain may require
further explanation and/or clarification. Accordingly, these slides and the information they contain should be
read in conjunction with past and future announcements made by Anteo and should not be relied upon as an
independent source of information. Please contact Anteo and/or refer to the Company's website for further
information.
The views expressed in this presentation contain information derived from publicly available sources that
have not been independently verified. No representation or warranty is made as to the accuracy,
completeness or reliability of the information.
Any forward looking statements in this presentation have been prepared on the basis of a number of
assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about
future events are subject to risks, uncertainties and other factors, many of which are outside Anteo
Diagnostics Ltd ’s control. Important factors that could cause actual results to differ materially from
assumptions or expectations expressed or implied in this presentation include known and unknown risks.
Because actual results could differ materially to assumptions made and Anteo’s current intentions, plans,
expectations and beliefs about the future, you are urged to view all forward looking statements contained in
this presentation with caution.
This presentation should not be relied on as a recommendation or forecast by Anteo Diagnostics Limited.
Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or
sell shares in any jurisdiction.
Anteo Diagnostics Limited I Investor Presentation 2
Anteo Company Profile
An Australian biotechnology company that develops,
manufactures and commercialises proprietary surface coatings
for health care, life sciences and beyond.
Anteo Diagnostics Limited I Investor Presentation 3
Mix&Go™
BiosensorsMembranes Microarrays Microtitre
plates
Particles
The surface you want on the surface you have.
Financial Snapshot – March 2015
Executive Team
Dr. Geoff Cumming – Chief Executive Officer
Dr. Joe Maeji – Chief Scientific Officer
Mr. Richard Martin – Chief Financial Officer
Dr. Tina Baumgartner – VP of Business Development
Mr. Joshua Soldo – VP of ScientificAffairs
Dr Rachel de las Heras – Head Commercial Development
Mr. Shaun Cooper – Head of Production
Board of Directors
Mr. Mark Bouris
Non-Executive Chairman
Dr. Geoff Cumming
Chief Executive Officer
Mr. Richard Martin
Executive Director
Ms. Sandra Andersen
Non-Executive Director
Dr. John Hurrell
Non-Executive Director
Anteo Diagnostics Limited I Investor Presentation 4
Shareholders 5,019
First Cape Mgt Pty Ltd 9.4%
Austcorp 190 Pty Ltd 3.9%
Nimrod Finance Ltd 2.4%
Corporate Snapshot
ASX ADO
Cash $6.8M
Market Cap. $78M
Av Daily Volume (30 d) 1,378,989
52 week high/low $0.28/$0.09
Shares on issue 844.8M
Top 20 29.78%
Directors/Staff 16%
Diagnostic Industry Drivers
Health Economics Point-of-Care Testing
PERCENT OF WW
HEALTHCARE SPENDING
USED ON DIAGNOSTICS
PERCENT OF MEDICAL
DECISION-MAKING
INFLUENCED BY DIAGNOSTICS
DIAGNOSTIC TESTING MOVES
FROM THE LABORATORY
TO THE POINT OF CARE
2% 70%
Diagnostics = critical medical decision-making
•  better patient outcomes
•  lives saved
•  reduced health care costs
Diagnostic test are moving closer to the:
•  patient
•  physician’s office
•  emergency vehicles
•  assisted living facilities
•  patient’s home
Anteo Diagnostics Limited I Investor Presentation 6
Cost Savings Miniaturisation
Mix&Go-The Secret Sauce
Anteo Diagnostics Limited I Investor Presentation 6
•  Ease of use
•  Performance
•  Cost
•  Manufacturability
Improves what’s possible; and makes the
impossible accessible
Platform Technology: Mix&Go Value Creation
Mix&Go™ is a universal double-sided molecular velcro:
The Mix&Go Difference
Anteo Diagnostics Limited I Investor Presentation 5
•  Uniquely suited for applications in diagnostics and life sciences
•  Binds fragile biomolecules gently yet strongly to synthetic surfaces
•  Addresses critical bottlenecks in test development:
•  Miniaturisation for point-of-care
•  Pressure to save cost in test development and manufacture
•  Family of products, over 50 formulations for different applications
Value Capture
Anteo participates in the value it creates to its partners.
The company has different revenue streams:
Value
Creation
Licensing:
•  Development Fees
•  License or Technology Access Fees
•  Royalties on sales from products containing Mix&Go
Value
Capture
R&D Agreements:
•  Paid R&D undertaken on partner’s behalf
OEM and Supply Agreements:
•  In house manufacture of Mix&Go-enhanced products
•  For B2B customers
AMG Products and Services:
•  Sales revenues
•  Provide easy way to experience the Mix&Go advantages
•  Provides partner with access to broad technical expertise
Anteo Diagnostics Limited I Investor Presentation 8
Growth Strategy
Anteo Diagnostics Limited I Investor Presentation 6
Anteo is implementing a five part growth strategy:
•  Licensing Anteo’s IP
•  Expanding Anteo’s Core Competencies & IP
•  Developing Anteo’s Product Pipeline
•  Exploring Anteo’s Blue Sky Opportunities
•  Acquisition of Synergistic Assets
Shareholder Value
Licensing Anteo’s IP - Example – PoC Device
Breathing life into a challenging project …
•
•
•
•
•
•
•
•
•
•
Global, well-known diversified company (2013 healthcare revenues: €10B)
Initial application: critical care – cardiac function
Six years in development
Clinically necessary performance not achieved
Pilot study with Mix&Go showed promise
12 month paid engagement to optimize one of two
Achieved clinical benchmark
system components
Demonstrated significant improvement on second component
Now engaged in paid project to optimize system holistically
Projected launch: 2015
Expectation: royalties on every test performed on the instrument
Anteo Diagnostics Limited I Investor Presentation 9
Licensing IP - Anteo’s Future Opportunities
Large global healthcare markets underpin revenue growth
potential
Anteo is targeting a number of diverse large and growing healthcare sectors
with Mix&Go. The compelling market opportunities include:
•  Bioseparations
•  Laboratory Diagnostics
•  Point-of-Care
• Rapid Test Products
• Life Science R&D
The total market size of these fields is in excess of $50B
Anteo Diagnostics Limited I Investor Presentation 10
Expanding Anteo’s Core Competencies & IP
Anteo Diagnostics Limited I Investor Presentation 10
AIM – To coat any surface in any format
1.  Particles
ü  Control protein density & particle uniformity
ü  Especially Nanoparticles (< 1 µm and specialising in <100 nm)
2.  Planar Surfaces
ü  Coat common surfaces used in life sciences regardless of hydrophobicity/
hydrophilicity profile
3.  Mix&Go Library
ü  25-50 new formulations
ü  Mix&Go for hydrophobic surfaces
ü  Cheaper Mix&Go for industrial applications
ü  Safer Mix&Go for in-vivo applications
Competencies together support Licensing & Blue Sky applications
Expanding Anteo’s Core Competencies & IP
Anteo Diagnostics Limited I Investor Presentation 10
Level 1: Positioning
Level 2: Developing Core Competency (IP and Know How)
IP Strategy
ü  Generation of Surface Coating Diversity. Granted.
Ø  Methods to generate libraries of different surfaces and screening thereof
ü  Use of Metal Complexes. Granted and US Divisional filed.
Ø  Use of metal complexes to bind proteins to surfaces
ü  Binding Systems. National Phase.
Ø  Use of metal polymers as coatings
ü  Method to remove or decrease interference in a sample.
ü  PoC1 sensor surface could further improve outcomes with the device.
ü  Coating Nanoparticles.
Ø  Conjugating Molecules to Particles. PCT Phase.
ü  Coating New Materials: new thermoplastics, steel, etc.
Ø  Heterofunctional Binding Systems. Provisional Phase.
Developing Anteo’s Product Pipeline
Anteo Diagnostics Limited I Investor Presentation 10
AIM – To demonstrate stable and effective products can be
made and sold on the Mix&Go surface
1. Mix&Go Solutions
ü  Mix&Go Sub-micron, Micro and Biosensor
ü  Mix&Go Plates & Mix&Go In-Vivo
2. Novel Mix&Go products
ü  AMG - Streptavidin coated plates and magnetic particles
ü  AMG – Coupling Kit (magnetic beads 1 µm)
ü  AMG – Activation Kit (latex particles 100-400 nm)
ü  AMG – Coupling Kit (gold particles 40 nm)
ü  AMG - Protein A/G/L Filtration Plate (bio-separations)
Builds technology and brand awareness. $$ & knowledge
acquired supports Core Competencies & Licensing
Exploring Anteo’s Blue Sky Opportunities
Anteo Diagnostics Limited I Investor Presentation 10
Exploring Anteo’s Blue Sky Opportunities
Not one market but multiple multi-billion $ markets
Attractive opportunities exist for Anteo
•  Several applications in cleantech and resources under evaluation in
collaboration with domain experts.
Anteo Diagnostics Limited I Investor Presentation 10
Bioseparations:
Ø  Purification of a biological material from mixture
Ø  Mix&Go can bind to:
•  bacteria, viruses, toxic metals, various
capture agents
Ø  Combined with:
•  Simple, cost effective magnetic separations
and membrane technologies.
Purification:
Water treatment, recycling oils, removing radio-isotopes
In Vivo:
Ø  Scaffolds (bone, artery, cartilage
replacement)
Ø  Wound dressings (sealants, artificial
membranes)
Ø  Drug delivery (drug eluting stents)
Ø  Implants (TiO2, IrO2 used as coatings
on vascular stents)
Acquisition of Synergistic Assets
Anteo Diagnostics Limited I Investor Presentation 10
Anteo is investigating the acquisition of companies that will
help act as a catalyst for commercialisation of Mix&Go.
Three key criteria:
ü  Cash Flow Positive
ü  Accretive and
ü  Technological Fit
Advisor appointed – reviewing opportunities
Planned Milestones for 2015
2015 2016
Anteo Diagnostics Limited I Investor Presentation 11
	
  
Advancing near-term value accretive opportunities that will translate
quickly into revenue….
ü  Feasibility agreement w/ global healthcare company for development of Point of Care device
ü  Entered into a paid Research and Collaboration Agreement with IMRA
ü  Strengthening existing partner relations by co-developing and co-marketing products
ü  Negotiations advancing with medical device company, extending our opportunities into in Vivo
ü  Two additional paid Research and Collaboration projects undertaken during the Q1 of CY 2015
ü  Mix&Go integrated in 100+ products at partner company
ü  Continue to launch 1 product/ quarter
ü  Adding distribution partners for Anteo’s Mix&Go and AMG product lines
ü  Advancing a proprietary product concept with large industry-wide potential
ü  Generating custom M&G formulations optimized for various surfaces and applications
ü  New patent application continues to build Anteo’s suite of patents using Mix&Go
Ø  Latest application builds on previously filed patents and strengthens our IP position
Anteo has several projects in advanced development and adds to its deal pipeline continuously
Anteo is set up for Growth
Anteo Diagnostics Limited I Investor Presentation 11
•  Mix&Go is a proprietary platform technology with broad applicability in
diagnostics, life sciences, bioseparations and beyond
•  Mix&Go is proven, licensed and gaining significant traction in commercial
markets
•  Mix&Go products provide easy access and credibility for customers
•  Strong near term value drivers
•  Focus on diagnostics and life sciences with expansion into bioseparations
provides Anteo significant revenue opportunities
•  Ready to develop opportunities in additional markets and execute long term
potential
•  Strong leadership - Board and management team in place to drive growth
•  Global team, resources and network to capitalise on growth opportunities
Contact Information
Thank you very much for you interest in Anteo Diagnostics
For more information please contact:
Anteo Diagnostics Limited I Investor Presentation 13
Dr.	
  Geoff	
  Cumming,	
  CEO	
  
E:	
  	
  	
  geoff.cumming@anteodx.com	
  
M:	
  +61	
  417	
  203	
  021	
  
Or download Anteo Investor
Relations App for latest ASX news,
share price and important company
updates.
Available under Anteo IR at App store and Google play
	
  

More Related Content

What's hot

Anteo Diagnostics Microcap Presentation October 2013
Anteo Diagnostics Microcap Presentation October 2013Anteo Diagnostics Microcap Presentation October 2013
Anteo Diagnostics Microcap Presentation October 2013Matt Sanderson
 
Multiplexing and Arraying in Lateral Flow Assays
Multiplexing and Arraying in Lateral Flow AssaysMultiplexing and Arraying in Lateral Flow Assays
Multiplexing and Arraying in Lateral Flow AssaysBrendan O'Farrell
 
Finnish biotech year, Tero Piispanen
Finnish biotech year, Tero Piispanen Finnish biotech year, Tero Piispanen
Finnish biotech year, Tero Piispanen Business Turku
 
HealthBIO 2021_PerkinElmer, leading with innovation - from COVID success into...
HealthBIO 2021_PerkinElmer, leading with innovation - from COVID success into...HealthBIO 2021_PerkinElmer, leading with innovation - from COVID success into...
HealthBIO 2021_PerkinElmer, leading with innovation - from COVID success into...Business Turku
 
HealthBIO 2021_Finnish biotech year 2021_Tero Piispanen
HealthBIO 2021_Finnish biotech year 2021_Tero Piispanen HealthBIO 2021_Finnish biotech year 2021_Tero Piispanen
HealthBIO 2021_Finnish biotech year 2021_Tero Piispanen Business Turku
 
HealthBIO 2020_Tero Piispanen_Turku Science Park
HealthBIO 2020_Tero Piispanen_Turku Science ParkHealthBIO 2020_Tero Piispanen_Turku Science Park
HealthBIO 2020_Tero Piispanen_Turku Science ParkBusiness Turku
 
Experiences from an IPO at AIM, Juho Jalkanen
Experiences from an IPO at AIM, Juho Jalkanen Experiences from an IPO at AIM, Juho Jalkanen
Experiences from an IPO at AIM, Juho Jalkanen Business Turku
 
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...Business Turku
 
A Trust-Centric Healthcare Journey | Full Presentation of PharmaLedger's 1st ...
A Trust-Centric Healthcare Journey | Full Presentation of PharmaLedger's 1st ...A Trust-Centric Healthcare Journey | Full Presentation of PharmaLedger's 1st ...
A Trust-Centric Healthcare Journey | Full Presentation of PharmaLedger's 1st ...PharmaLedger
 
Collaboration through TaNeDS programme, Keiko Tamai
Collaboration through TaNeDS programme, Keiko Tamai Collaboration through TaNeDS programme, Keiko Tamai
Collaboration through TaNeDS programme, Keiko Tamai Business Turku
 
HealthBIO 2021,_The InFlames Flagship_Timo Veromaa
HealthBIO 2021,_The InFlames Flagship_Timo VeromaaHealthBIO 2021,_The InFlames Flagship_Timo Veromaa
HealthBIO 2021,_The InFlames Flagship_Timo VeromaaBusiness Turku
 
Importance Of Patents In The Life Sciences Industry
Importance Of Patents In The Life Sciences IndustryImportance Of Patents In The Life Sciences Industry
Importance Of Patents In The Life Sciences Industrybatane
 
VeriTeQ Presentation at the Global Online CEO Conference July 2014
VeriTeQ Presentation at the Global Online CEO Conference July 2014VeriTeQ Presentation at the Global Online CEO Conference July 2014
VeriTeQ Presentation at the Global Online CEO Conference July 2014RedChip Companies, Inc.
 
OSMA: Orthopedic Industry's Top Regulatory Challenges and Opportunities
OSMA: Orthopedic Industry's Top Regulatory Challenges and OpportunitiesOSMA: Orthopedic Industry's Top Regulatory Challenges and Opportunities
OSMA: Orthopedic Industry's Top Regulatory Challenges and OpportunitiesApril Bright
 
Leveraging Data to Develop, Execute and Exceed the Expectations of Your Regu...
Leveraging Data to Develop, Execute and Exceed the Expectations of  Your Regu...Leveraging Data to Develop, Execute and Exceed the Expectations of  Your Regu...
Leveraging Data to Develop, Execute and Exceed the Expectations of Your Regu...April Bright
 

What's hot (20)

DCN Company Profile 2015
DCN Company Profile 2015DCN Company Profile 2015
DCN Company Profile 2015
 
Anteo Diagnostics Microcap Presentation October 2013
Anteo Diagnostics Microcap Presentation October 2013Anteo Diagnostics Microcap Presentation October 2013
Anteo Diagnostics Microcap Presentation October 2013
 
Multiplexing and Arraying in Lateral Flow Assays
Multiplexing and Arraying in Lateral Flow AssaysMultiplexing and Arraying in Lateral Flow Assays
Multiplexing and Arraying in Lateral Flow Assays
 
Finnish biotech year, Tero Piispanen
Finnish biotech year, Tero Piispanen Finnish biotech year, Tero Piispanen
Finnish biotech year, Tero Piispanen
 
HealthBIO 2021_PerkinElmer, leading with innovation - from COVID success into...
HealthBIO 2021_PerkinElmer, leading with innovation - from COVID success into...HealthBIO 2021_PerkinElmer, leading with innovation - from COVID success into...
HealthBIO 2021_PerkinElmer, leading with innovation - from COVID success into...
 
Ideaken 2016
Ideaken 2016Ideaken 2016
Ideaken 2016
 
HealthBIO 2021_Finnish biotech year 2021_Tero Piispanen
HealthBIO 2021_Finnish biotech year 2021_Tero Piispanen HealthBIO 2021_Finnish biotech year 2021_Tero Piispanen
HealthBIO 2021_Finnish biotech year 2021_Tero Piispanen
 
HealthBIO 2020_Tero Piispanen_Turku Science Park
HealthBIO 2020_Tero Piispanen_Turku Science ParkHealthBIO 2020_Tero Piispanen_Turku Science Park
HealthBIO 2020_Tero Piispanen_Turku Science Park
 
Experiences from an IPO at AIM, Juho Jalkanen
Experiences from an IPO at AIM, Juho Jalkanen Experiences from an IPO at AIM, Juho Jalkanen
Experiences from an IPO at AIM, Juho Jalkanen
 
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...
 
A Trust-Centric Healthcare Journey | Full Presentation of PharmaLedger's 1st ...
A Trust-Centric Healthcare Journey | Full Presentation of PharmaLedger's 1st ...A Trust-Centric Healthcare Journey | Full Presentation of PharmaLedger's 1st ...
A Trust-Centric Healthcare Journey | Full Presentation of PharmaLedger's 1st ...
 
Collaboration through TaNeDS programme, Keiko Tamai
Collaboration through TaNeDS programme, Keiko Tamai Collaboration through TaNeDS programme, Keiko Tamai
Collaboration through TaNeDS programme, Keiko Tamai
 
HealthBIO 2021,_The InFlames Flagship_Timo Veromaa
HealthBIO 2021,_The InFlames Flagship_Timo VeromaaHealthBIO 2021,_The InFlames Flagship_Timo Veromaa
HealthBIO 2021,_The InFlames Flagship_Timo Veromaa
 
Scio
ScioScio
Scio
 
07 vteq
07 vteq07 vteq
07 vteq
 
Importance Of Patents In The Life Sciences Industry
Importance Of Patents In The Life Sciences IndustryImportance Of Patents In The Life Sciences Industry
Importance Of Patents In The Life Sciences Industry
 
VTEQ Presentation july 2014
VTEQ Presentation july 2014VTEQ Presentation july 2014
VTEQ Presentation july 2014
 
VeriTeQ Presentation at the Global Online CEO Conference July 2014
VeriTeQ Presentation at the Global Online CEO Conference July 2014VeriTeQ Presentation at the Global Online CEO Conference July 2014
VeriTeQ Presentation at the Global Online CEO Conference July 2014
 
OSMA: Orthopedic Industry's Top Regulatory Challenges and Opportunities
OSMA: Orthopedic Industry's Top Regulatory Challenges and OpportunitiesOSMA: Orthopedic Industry's Top Regulatory Challenges and Opportunities
OSMA: Orthopedic Industry's Top Regulatory Challenges and Opportunities
 
Leveraging Data to Develop, Execute and Exceed the Expectations of Your Regu...
Leveraging Data to Develop, Execute and Exceed the Expectations of  Your Regu...Leveraging Data to Develop, Execute and Exceed the Expectations of  Your Regu...
Leveraging Data to Develop, Execute and Exceed the Expectations of Your Regu...
 

Similar to Anteo Technologies - New York presentation 2015

Bilcare corporate presentation
Bilcare corporate presentationBilcare corporate presentation
Bilcare corporate presentationBilcareltd
 
DuPont Presents at Jefferies 10th Annual Global Industrials Conference
DuPont Presents at Jefferies 10th Annual Global Industrials ConferenceDuPont Presents at Jefferies 10th Annual Global Industrials Conference
DuPont Presents at Jefferies 10th Annual Global Industrials ConferenceDupontInv
 
Venture Incubation
Venture IncubationVenture Incubation
Venture Incubationjagan339
 
How to Leverage Engineering & R&D From India and China in the Med Tech Business
How to Leverage Engineering & R&D From India and China in the Med Tech BusinessHow to Leverage Engineering & R&D From India and China in the Med Tech Business
How to Leverage Engineering & R&D From India and China in the Med Tech BusinessUBMCanon
 
INNOVATION SHOWCASE A5 BOOKLET v6 (2) A
INNOVATION SHOWCASE A5 BOOKLET v6 (2) AINNOVATION SHOWCASE A5 BOOKLET v6 (2) A
INNOVATION SHOWCASE A5 BOOKLET v6 (2) AGary atkinson-hope
 
Viropro investor presentation 01_apr11
Viropro investor presentation 01_apr11Viropro investor presentation 01_apr11
Viropro investor presentation 01_apr11rvdatar
 
Advanced Medical Isotope Corp. Investor Presentation
Advanced Medical Isotope Corp. Investor PresentationAdvanced Medical Isotope Corp. Investor Presentation
Advanced Medical Isotope Corp. Investor PresentationRedChip Companies, Inc.
 
2015 Company & Product Introduction
2015 Company & Product Introduction2015 Company & Product Introduction
2015 Company & Product IntroductionKei Lim
 
Aptuit Consulting Inc
Aptuit Consulting IncAptuit Consulting Inc
Aptuit Consulting Incalonso_guzman
 
X Sector Disruption | CIO Leaders Summit 2015 | The Propell Group
X Sector Disruption | CIO Leaders Summit 2015 | The Propell GroupX Sector Disruption | CIO Leaders Summit 2015 | The Propell Group
X Sector Disruption | CIO Leaders Summit 2015 | The Propell GroupJulien de Salaberry
 
PreScouter + GE Healthcare: How will the Internet of Things Impact your Indus...
PreScouter + GE Healthcare: How will the Internet of Things Impact your Indus...PreScouter + GE Healthcare: How will the Internet of Things Impact your Indus...
PreScouter + GE Healthcare: How will the Internet of Things Impact your Indus...PreScouter
 
Technology: High value manufacturing
Technology: High value manufacturingTechnology: High value manufacturing
Technology: High value manufacturingbisgovuk
 
Baml conference 2015 final
Baml conference 2015   finalBaml conference 2015   final
Baml conference 2015 finalDupontInv
 
Dupont Slides Sanford Bernstein final 5 27-14
Dupont Slides Sanford Bernstein final 5 27-14Dupont Slides Sanford Bernstein final 5 27-14
Dupont Slides Sanford Bernstein final 5 27-14DupontInv
 
Hair Boom (Hair Bang) Product Introduction - Laser Helmet for Hair Loss
Hair Boom (Hair Bang) Product Introduction - Laser Helmet for Hair LossHair Boom (Hair Bang) Product Introduction - Laser Helmet for Hair Loss
Hair Boom (Hair Bang) Product Introduction - Laser Helmet for Hair LossWONTECH
 
Biocon FY12 full year results Press Release + Fact Sheet
Biocon FY12 full year results Press Release + Fact SheetBiocon FY12 full year results Press Release + Fact Sheet
Biocon FY12 full year results Press Release + Fact SheetBiocon
 

Similar to Anteo Technologies - New York presentation 2015 (20)

Bilcare corporate presentation
Bilcare corporate presentationBilcare corporate presentation
Bilcare corporate presentation
 
DuPont Presents at Jefferies 10th Annual Global Industrials Conference
DuPont Presents at Jefferies 10th Annual Global Industrials ConferenceDuPont Presents at Jefferies 10th Annual Global Industrials Conference
DuPont Presents at Jefferies 10th Annual Global Industrials Conference
 
Venture Incubation
Venture IncubationVenture Incubation
Venture Incubation
 
How to Leverage Engineering & R&D From India and China in the Med Tech Business
How to Leverage Engineering & R&D From India and China in the Med Tech BusinessHow to Leverage Engineering & R&D From India and China in the Med Tech Business
How to Leverage Engineering & R&D From India and China in the Med Tech Business
 
INNOVATION SHOWCASE A5 BOOKLET v6 (2) A
INNOVATION SHOWCASE A5 BOOKLET v6 (2) AINNOVATION SHOWCASE A5 BOOKLET v6 (2) A
INNOVATION SHOWCASE A5 BOOKLET v6 (2) A
 
Viropro investor presentation 01_apr11
Viropro investor presentation 01_apr11Viropro investor presentation 01_apr11
Viropro investor presentation 01_apr11
 
Advanced Medical Isotope Corp. Investor Presentation
Advanced Medical Isotope Corp. Investor PresentationAdvanced Medical Isotope Corp. Investor Presentation
Advanced Medical Isotope Corp. Investor Presentation
 
AMI Investor Presentation
AMI Investor PresentationAMI Investor Presentation
AMI Investor Presentation
 
2015 Company & Product Introduction
2015 Company & Product Introduction2015 Company & Product Introduction
2015 Company & Product Introduction
 
Aptuit Consulting Inc
Aptuit Consulting IncAptuit Consulting Inc
Aptuit Consulting Inc
 
X Sector Disruption | CIO Leaders Summit 2015 | The Propell Group
X Sector Disruption | CIO Leaders Summit 2015 | The Propell GroupX Sector Disruption | CIO Leaders Summit 2015 | The Propell Group
X Sector Disruption | CIO Leaders Summit 2015 | The Propell Group
 
Truth Biomedical
Truth BiomedicalTruth Biomedical
Truth Biomedical
 
PreScouter + GE Healthcare: How will the Internet of Things Impact your Indus...
PreScouter + GE Healthcare: How will the Internet of Things Impact your Indus...PreScouter + GE Healthcare: How will the Internet of Things Impact your Indus...
PreScouter + GE Healthcare: How will the Internet of Things Impact your Indus...
 
Technology: High value manufacturing
Technology: High value manufacturingTechnology: High value manufacturing
Technology: High value manufacturing
 
Mozzi quit
Mozzi quitMozzi quit
Mozzi quit
 
MozziQuit
MozziQuitMozziQuit
MozziQuit
 
Baml conference 2015 final
Baml conference 2015   finalBaml conference 2015   final
Baml conference 2015 final
 
Dupont Slides Sanford Bernstein final 5 27-14
Dupont Slides Sanford Bernstein final 5 27-14Dupont Slides Sanford Bernstein final 5 27-14
Dupont Slides Sanford Bernstein final 5 27-14
 
Hair Boom (Hair Bang) Product Introduction - Laser Helmet for Hair Loss
Hair Boom (Hair Bang) Product Introduction - Laser Helmet for Hair LossHair Boom (Hair Bang) Product Introduction - Laser Helmet for Hair Loss
Hair Boom (Hair Bang) Product Introduction - Laser Helmet for Hair Loss
 
Biocon FY12 full year results Press Release + Fact Sheet
Biocon FY12 full year results Press Release + Fact SheetBiocon FY12 full year results Press Release + Fact Sheet
Biocon FY12 full year results Press Release + Fact Sheet
 

More from Matt Sanderson

Anteo Technologies Lateral Flow
Anteo Technologies Lateral FlowAnteo Technologies Lateral Flow
Anteo Technologies Lateral FlowMatt Sanderson
 
A Novel Chemistry to Couple Antibodies and Challenging Proteins to Luminex M...
A Novel Chemistry to  Couple Antibodies and Challenging Proteins to Luminex M...A Novel Chemistry to  Couple Antibodies and Challenging Proteins to Luminex M...
A Novel Chemistry to Couple Antibodies and Challenging Proteins to Luminex M...Matt Sanderson
 
ASX Australian Biotech Market cap list
ASX Australian Biotech Market cap listASX Australian Biotech Market cap list
ASX Australian Biotech Market cap listMatt Sanderson
 
Multiplex energy metabolism
Multiplex energy metabolismMultiplex energy metabolism
Multiplex energy metabolismMatt Sanderson
 
Novel methods in Bioseparations
Novel methods in BioseparationsNovel methods in Bioseparations
Novel methods in BioseparationsMatt Sanderson
 
Silicon battery Presentation - Lithium Ion
Silicon battery Presentation - Lithium IonSilicon battery Presentation - Lithium Ion
Silicon battery Presentation - Lithium IonMatt Sanderson
 
Magnetic-bead-coatings-today-and-tomorrow
Magnetic-bead-coatings-today-and-tomorrowMagnetic-bead-coatings-today-and-tomorrow
Magnetic-bead-coatings-today-and-tomorrowMatt Sanderson
 
High Sensitivity Troponin
High Sensitivity TroponinHigh Sensitivity Troponin
High Sensitivity TroponinMatt Sanderson
 

More from Matt Sanderson (9)

Anteo Technologies Lateral Flow
Anteo Technologies Lateral FlowAnteo Technologies Lateral Flow
Anteo Technologies Lateral Flow
 
A Novel Chemistry to Couple Antibodies and Challenging Proteins to Luminex M...
A Novel Chemistry to  Couple Antibodies and Challenging Proteins to Luminex M...A Novel Chemistry to  Couple Antibodies and Challenging Proteins to Luminex M...
A Novel Chemistry to Couple Antibodies and Challenging Proteins to Luminex M...
 
ASX Australian Biotech Market cap list
ASX Australian Biotech Market cap listASX Australian Biotech Market cap list
ASX Australian Biotech Market cap list
 
Multiplex energy metabolism
Multiplex energy metabolismMultiplex energy metabolism
Multiplex energy metabolism
 
Novel methods in Bioseparations
Novel methods in BioseparationsNovel methods in Bioseparations
Novel methods in Bioseparations
 
Silicon battery Presentation - Lithium Ion
Silicon battery Presentation - Lithium IonSilicon battery Presentation - Lithium Ion
Silicon battery Presentation - Lithium Ion
 
Top 10 IVD Companies
Top 10 IVD CompaniesTop 10 IVD Companies
Top 10 IVD Companies
 
Magnetic-bead-coatings-today-and-tomorrow
Magnetic-bead-coatings-today-and-tomorrowMagnetic-bead-coatings-today-and-tomorrow
Magnetic-bead-coatings-today-and-tomorrow
 
High Sensitivity Troponin
High Sensitivity TroponinHigh Sensitivity Troponin
High Sensitivity Troponin
 

Recently uploaded

ARTHRITIS.pptx Prepared by monika gopal Tutor
ARTHRITIS.pptx Prepared  by monika gopal TutorARTHRITIS.pptx Prepared  by monika gopal Tutor
ARTHRITIS.pptx Prepared by monika gopal TutorNehaKewat
 
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....sharyurangari111
 
Three Keys to a Successful Margin: Charges, Costs, and Labor
Three Keys to a Successful Margin: Charges, Costs, and LaborThree Keys to a Successful Margin: Charges, Costs, and Labor
Three Keys to a Successful Margin: Charges, Costs, and LaborHealth Catalyst
 
21 NEMT Trends & Statistics to Know in 2024
21 NEMT Trends & Statistics to Know in 202421 NEMT Trends & Statistics to Know in 2024
21 NEMT Trends & Statistics to Know in 2024Traumasoft LLC
 
Health literacies in marginalised communities LILAC 24.pptx
Health literacies in marginalised communities LILAC 24.pptxHealth literacies in marginalised communities LILAC 24.pptx
Health literacies in marginalised communities LILAC 24.pptxPamela McKinney
 
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdfAnatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdfhezamzaki1
 
Pharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxPharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxCliniminds India
 
Introduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin BenefitsIntroduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin Benefitssahilgabhane29
 
Basics of Giant Cell Tumor of bone (GCTB)
Basics of Giant Cell Tumor of bone (GCTB)Basics of Giant Cell Tumor of bone (GCTB)
Basics of Giant Cell Tumor of bone (GCTB)bishwabandhuniraula
 
ACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the CuriousACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the CuriousKR_Barker
 
Identifying Signs of Mental Health Presentation (1).pptx
Identifying Signs of Mental Health Presentation (1).pptxIdentifying Signs of Mental Health Presentation (1).pptx
Identifying Signs of Mental Health Presentation (1).pptxsandhulove46637
 
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
LARYNGEAL CANCER.pptx  Prepared by Neha KewatLARYNGEAL CANCER.pptx  Prepared by Neha Kewat
LARYNGEAL CANCER.pptx Prepared by Neha KewatNehaKewat
 
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdfCompliatric Where Compliance Happens
 
Eating Disorders in Athletes I Sports Psychology
Eating Disorders in Athletes I Sports PsychologyEating Disorders in Athletes I Sports Psychology
Eating Disorders in Athletes I Sports Psychologyshantisphysio
 
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES 11
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES  11FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES  11
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES 11crzljavier
 
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptxNEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptxHanineHassan2
 
Empathy Is a Stress Response - Choose Compassion instead
Empathy Is a Stress Response - Choose Compassion insteadEmpathy Is a Stress Response - Choose Compassion instead
Empathy Is a Stress Response - Choose Compassion insteadAlex Clapson
 
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdfDolisha Warbi
 

Recently uploaded (20)

ARTHRITIS.pptx Prepared by monika gopal Tutor
ARTHRITIS.pptx Prepared  by monika gopal TutorARTHRITIS.pptx Prepared  by monika gopal Tutor
ARTHRITIS.pptx Prepared by monika gopal Tutor
 
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
 
Three Keys to a Successful Margin: Charges, Costs, and Labor
Three Keys to a Successful Margin: Charges, Costs, and LaborThree Keys to a Successful Margin: Charges, Costs, and Labor
Three Keys to a Successful Margin: Charges, Costs, and Labor
 
21 NEMT Trends & Statistics to Know in 2024
21 NEMT Trends & Statistics to Know in 202421 NEMT Trends & Statistics to Know in 2024
21 NEMT Trends & Statistics to Know in 2024
 
Health literacies in marginalised communities LILAC 24.pptx
Health literacies in marginalised communities LILAC 24.pptxHealth literacies in marginalised communities LILAC 24.pptx
Health literacies in marginalised communities LILAC 24.pptx
 
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdfAnatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
 
Pharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxPharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptx
 
Introduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin BenefitsIntroduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin Benefits
 
Basics of Giant Cell Tumor of bone (GCTB)
Basics of Giant Cell Tumor of bone (GCTB)Basics of Giant Cell Tumor of bone (GCTB)
Basics of Giant Cell Tumor of bone (GCTB)
 
ACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the CuriousACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the Curious
 
Painting Rats White Angers Them to No End
Painting Rats White Angers Them to No EndPainting Rats White Angers Them to No End
Painting Rats White Angers Them to No End
 
Identifying Signs of Mental Health Presentation (1).pptx
Identifying Signs of Mental Health Presentation (1).pptxIdentifying Signs of Mental Health Presentation (1).pptx
Identifying Signs of Mental Health Presentation (1).pptx
 
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
LARYNGEAL CANCER.pptx  Prepared by Neha KewatLARYNGEAL CANCER.pptx  Prepared by Neha Kewat
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
 
The Power of Active listening - Tool in effective communication.pdf
The Power of Active listening - Tool in effective communication.pdfThe Power of Active listening - Tool in effective communication.pdf
The Power of Active listening - Tool in effective communication.pdf
 
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf
2024 Compliatric Webianr Series - Contracts and MOUs from a HRSA Perspective.pdf
 
Eating Disorders in Athletes I Sports Psychology
Eating Disorders in Athletes I Sports PsychologyEating Disorders in Athletes I Sports Psychology
Eating Disorders in Athletes I Sports Psychology
 
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES 11
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES  11FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES  11
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES 11
 
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptxNEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
NEONATAL RESPIRATORY CARE FROM A PHYSIO POV.pptx
 
Empathy Is a Stress Response - Choose Compassion instead
Empathy Is a Stress Response - Choose Compassion insteadEmpathy Is a Stress Response - Choose Compassion instead
Empathy Is a Stress Response - Choose Compassion instead
 
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
 

Anteo Technologies - New York presentation 2015

  • 1. Anteo Diagnostics Limited (ASX:ADO) March 2015 Presented by Dr Geoff Cumming CEO
  • 2. Forward Looking Statement The purpose of the presentation is to provide an update of the business of Anteo Diagnostics (ASX:ADO). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Anteo and should not be relied upon as an independent source of information. Please contact Anteo and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Anteo Diagnostics Ltd ’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Anteo’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. This presentation should not be relied on as a recommendation or forecast by Anteo Diagnostics Limited. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. Anteo Diagnostics Limited I Investor Presentation 2
  • 3. Anteo Company Profile An Australian biotechnology company that develops, manufactures and commercialises proprietary surface coatings for health care, life sciences and beyond. Anteo Diagnostics Limited I Investor Presentation 3 Mix&Go™ BiosensorsMembranes Microarrays Microtitre plates Particles The surface you want on the surface you have.
  • 4. Financial Snapshot – March 2015 Executive Team Dr. Geoff Cumming – Chief Executive Officer Dr. Joe Maeji – Chief Scientific Officer Mr. Richard Martin – Chief Financial Officer Dr. Tina Baumgartner – VP of Business Development Mr. Joshua Soldo – VP of ScientificAffairs Dr Rachel de las Heras – Head Commercial Development Mr. Shaun Cooper – Head of Production Board of Directors Mr. Mark Bouris Non-Executive Chairman Dr. Geoff Cumming Chief Executive Officer Mr. Richard Martin Executive Director Ms. Sandra Andersen Non-Executive Director Dr. John Hurrell Non-Executive Director Anteo Diagnostics Limited I Investor Presentation 4 Shareholders 5,019 First Cape Mgt Pty Ltd 9.4% Austcorp 190 Pty Ltd 3.9% Nimrod Finance Ltd 2.4% Corporate Snapshot ASX ADO Cash $6.8M Market Cap. $78M Av Daily Volume (30 d) 1,378,989 52 week high/low $0.28/$0.09 Shares on issue 844.8M Top 20 29.78% Directors/Staff 16%
  • 5. Diagnostic Industry Drivers Health Economics Point-of-Care Testing PERCENT OF WW HEALTHCARE SPENDING USED ON DIAGNOSTICS PERCENT OF MEDICAL DECISION-MAKING INFLUENCED BY DIAGNOSTICS DIAGNOSTIC TESTING MOVES FROM THE LABORATORY TO THE POINT OF CARE 2% 70% Diagnostics = critical medical decision-making •  better patient outcomes •  lives saved •  reduced health care costs Diagnostic test are moving closer to the: •  patient •  physician’s office •  emergency vehicles •  assisted living facilities •  patient’s home Anteo Diagnostics Limited I Investor Presentation 6 Cost Savings Miniaturisation
  • 6. Mix&Go-The Secret Sauce Anteo Diagnostics Limited I Investor Presentation 6 •  Ease of use •  Performance •  Cost •  Manufacturability Improves what’s possible; and makes the impossible accessible
  • 7. Platform Technology: Mix&Go Value Creation Mix&Go™ is a universal double-sided molecular velcro: The Mix&Go Difference Anteo Diagnostics Limited I Investor Presentation 5 •  Uniquely suited for applications in diagnostics and life sciences •  Binds fragile biomolecules gently yet strongly to synthetic surfaces •  Addresses critical bottlenecks in test development: •  Miniaturisation for point-of-care •  Pressure to save cost in test development and manufacture •  Family of products, over 50 formulations for different applications
  • 8. Value Capture Anteo participates in the value it creates to its partners. The company has different revenue streams: Value Creation Licensing: •  Development Fees •  License or Technology Access Fees •  Royalties on sales from products containing Mix&Go Value Capture R&D Agreements: •  Paid R&D undertaken on partner’s behalf OEM and Supply Agreements: •  In house manufacture of Mix&Go-enhanced products •  For B2B customers AMG Products and Services: •  Sales revenues •  Provide easy way to experience the Mix&Go advantages •  Provides partner with access to broad technical expertise Anteo Diagnostics Limited I Investor Presentation 8
  • 9. Growth Strategy Anteo Diagnostics Limited I Investor Presentation 6 Anteo is implementing a five part growth strategy: •  Licensing Anteo’s IP •  Expanding Anteo’s Core Competencies & IP •  Developing Anteo’s Product Pipeline •  Exploring Anteo’s Blue Sky Opportunities •  Acquisition of Synergistic Assets Shareholder Value
  • 10. Licensing Anteo’s IP - Example – PoC Device Breathing life into a challenging project … • • • • • • • • • • Global, well-known diversified company (2013 healthcare revenues: €10B) Initial application: critical care – cardiac function Six years in development Clinically necessary performance not achieved Pilot study with Mix&Go showed promise 12 month paid engagement to optimize one of two Achieved clinical benchmark system components Demonstrated significant improvement on second component Now engaged in paid project to optimize system holistically Projected launch: 2015 Expectation: royalties on every test performed on the instrument Anteo Diagnostics Limited I Investor Presentation 9
  • 11. Licensing IP - Anteo’s Future Opportunities Large global healthcare markets underpin revenue growth potential Anteo is targeting a number of diverse large and growing healthcare sectors with Mix&Go. The compelling market opportunities include: •  Bioseparations •  Laboratory Diagnostics •  Point-of-Care • Rapid Test Products • Life Science R&D The total market size of these fields is in excess of $50B Anteo Diagnostics Limited I Investor Presentation 10
  • 12. Expanding Anteo’s Core Competencies & IP Anteo Diagnostics Limited I Investor Presentation 10 AIM – To coat any surface in any format 1.  Particles ü  Control protein density & particle uniformity ü  Especially Nanoparticles (< 1 µm and specialising in <100 nm) 2.  Planar Surfaces ü  Coat common surfaces used in life sciences regardless of hydrophobicity/ hydrophilicity profile 3.  Mix&Go Library ü  25-50 new formulations ü  Mix&Go for hydrophobic surfaces ü  Cheaper Mix&Go for industrial applications ü  Safer Mix&Go for in-vivo applications Competencies together support Licensing & Blue Sky applications
  • 13. Expanding Anteo’s Core Competencies & IP Anteo Diagnostics Limited I Investor Presentation 10 Level 1: Positioning Level 2: Developing Core Competency (IP and Know How) IP Strategy ü  Generation of Surface Coating Diversity. Granted. Ø  Methods to generate libraries of different surfaces and screening thereof ü  Use of Metal Complexes. Granted and US Divisional filed. Ø  Use of metal complexes to bind proteins to surfaces ü  Binding Systems. National Phase. Ø  Use of metal polymers as coatings ü  Method to remove or decrease interference in a sample. ü  PoC1 sensor surface could further improve outcomes with the device. ü  Coating Nanoparticles. Ø  Conjugating Molecules to Particles. PCT Phase. ü  Coating New Materials: new thermoplastics, steel, etc. Ø  Heterofunctional Binding Systems. Provisional Phase.
  • 14. Developing Anteo’s Product Pipeline Anteo Diagnostics Limited I Investor Presentation 10 AIM – To demonstrate stable and effective products can be made and sold on the Mix&Go surface 1. Mix&Go Solutions ü  Mix&Go Sub-micron, Micro and Biosensor ü  Mix&Go Plates & Mix&Go In-Vivo 2. Novel Mix&Go products ü  AMG - Streptavidin coated plates and magnetic particles ü  AMG – Coupling Kit (magnetic beads 1 µm) ü  AMG – Activation Kit (latex particles 100-400 nm) ü  AMG – Coupling Kit (gold particles 40 nm) ü  AMG - Protein A/G/L Filtration Plate (bio-separations) Builds technology and brand awareness. $$ & knowledge acquired supports Core Competencies & Licensing
  • 15. Exploring Anteo’s Blue Sky Opportunities Anteo Diagnostics Limited I Investor Presentation 10
  • 16. Exploring Anteo’s Blue Sky Opportunities Not one market but multiple multi-billion $ markets Attractive opportunities exist for Anteo •  Several applications in cleantech and resources under evaluation in collaboration with domain experts. Anteo Diagnostics Limited I Investor Presentation 10 Bioseparations: Ø  Purification of a biological material from mixture Ø  Mix&Go can bind to: •  bacteria, viruses, toxic metals, various capture agents Ø  Combined with: •  Simple, cost effective magnetic separations and membrane technologies. Purification: Water treatment, recycling oils, removing radio-isotopes In Vivo: Ø  Scaffolds (bone, artery, cartilage replacement) Ø  Wound dressings (sealants, artificial membranes) Ø  Drug delivery (drug eluting stents) Ø  Implants (TiO2, IrO2 used as coatings on vascular stents)
  • 17. Acquisition of Synergistic Assets Anteo Diagnostics Limited I Investor Presentation 10 Anteo is investigating the acquisition of companies that will help act as a catalyst for commercialisation of Mix&Go. Three key criteria: ü  Cash Flow Positive ü  Accretive and ü  Technological Fit Advisor appointed – reviewing opportunities
  • 18. Planned Milestones for 2015 2015 2016 Anteo Diagnostics Limited I Investor Presentation 11   Advancing near-term value accretive opportunities that will translate quickly into revenue…. ü  Feasibility agreement w/ global healthcare company for development of Point of Care device ü  Entered into a paid Research and Collaboration Agreement with IMRA ü  Strengthening existing partner relations by co-developing and co-marketing products ü  Negotiations advancing with medical device company, extending our opportunities into in Vivo ü  Two additional paid Research and Collaboration projects undertaken during the Q1 of CY 2015 ü  Mix&Go integrated in 100+ products at partner company ü  Continue to launch 1 product/ quarter ü  Adding distribution partners for Anteo’s Mix&Go and AMG product lines ü  Advancing a proprietary product concept with large industry-wide potential ü  Generating custom M&G formulations optimized for various surfaces and applications ü  New patent application continues to build Anteo’s suite of patents using Mix&Go Ø  Latest application builds on previously filed patents and strengthens our IP position Anteo has several projects in advanced development and adds to its deal pipeline continuously
  • 19. Anteo is set up for Growth Anteo Diagnostics Limited I Investor Presentation 11 •  Mix&Go is a proprietary platform technology with broad applicability in diagnostics, life sciences, bioseparations and beyond •  Mix&Go is proven, licensed and gaining significant traction in commercial markets •  Mix&Go products provide easy access and credibility for customers •  Strong near term value drivers •  Focus on diagnostics and life sciences with expansion into bioseparations provides Anteo significant revenue opportunities •  Ready to develop opportunities in additional markets and execute long term potential •  Strong leadership - Board and management team in place to drive growth •  Global team, resources and network to capitalise on growth opportunities
  • 20. Contact Information Thank you very much for you interest in Anteo Diagnostics For more information please contact: Anteo Diagnostics Limited I Investor Presentation 13 Dr.  Geoff  Cumming,  CEO   E:      geoff.cumming@anteodx.com   M:  +61  417  203  021   Or download Anteo Investor Relations App for latest ASX news, share price and important company updates. Available under Anteo IR at App store and Google play